Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Chunghwa Chemical Synthesis & Biotech Co Debt-to-Equity Related Terms
Chunghwa Chemical Synthesis & Biotech Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co Debt-to-Equity Chart
Chunghwa Chemical Synthesis & Biotech Co Annual Data
TPE:1762 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chunghwa Chemical Synthesis & Biotech Co Debt-to-Equity vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Debt-to-Equity of 0.24 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. This is 14% below median its historical median of 0.28. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #575 out of 966 companies in the Biotechnology industry, placing it in the top 59.5%.
Is Chunghwa Chemical Synthesis & Biotech Co's Debt-to-Equity too high?
Chunghwa Chemical Synthesis & Biotech Co's current Debt-to-Equity of 0.24 is 14% below median its 10-year median of 0.28. The Biotechnology industry median Debt-to-Equity is 0.15. Chunghwa Chemical Synthesis & Biotech Co's value of 0.24 is 60% above this industry median. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #575 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #575 out of 966 companies for Debt-to-Equity. This places Chunghwa Chemical Synthesis & Biotech Co in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Chunghwa Chemical Synthesis & Biotech Co's value of 0.24 is 60% above this benchmark. While the company's 10-year median is 0.28 vs. the industry median of 0.15, Chunghwa Chemical Synthesis & Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chunghwa Chemical Synthesis & Biotech Co's current Debt-to-Equity of 0.24 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current Debt-to-Equity is 0.24, which is 14% below median its own 10-year median of 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$37.99, compared to a current price of NT$33.70 — trading 11.3% below its estimated fair value. The current Debt-to-Equity is 0.24, which is 14% below median its 10-year median of 0.28 and 60% above the Biotechnology industry median of 0.15. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Debt-to-Equity is 0.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued.
The current stock price of NT$33.70 is trading 11.3% below its estimated GF Value™ of NT$37.99.
GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Modestly Undervalued.
Key valuation signals for TPE:1762:
Debt-to-Equity: 0.24 (14% below median its 10-year median of 0.28)
GF Value™: NT$37.99 vs. price of NT$33.70 (11.3% below fair value)
Industry Position: 60% above the Biotechnology median (#575 of 966)
No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
67GF Score
Get the complete analysis for TPE:1762
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1762 has been successfully added to your 
